Novo Nordisk ® through 2022 1 on iation iation on s (GHD) esults 2 Clinical milestones 1 H1 2022 US decision Phase 1 results CN submission Regulatory milestones 1 H2 2022 Phase 2 results Phase 3a results Phase 1 results PDS290 variant: EU decision Phase 3 initiation Phase 1 results US/EU submission (GHD) Phase 3 treatment 3 Phase 3a results (HwI) 4 US/JP submission (HwI) Phase 2 initiation US submission Phase 2 initiation y completed. 3 First patient first in Q4 2021, which is solely for baselining purposes th inhibitors; ATTR-CM: Transthyretin Amyloid Cardiomyopathy
Download PDF file